Pharmaron Beijing Co.Ltd(300759) (Beijing) new drug Technology Co., Ltd. independent directors’ prior approval opinions on matters related to the 18th meeting of the second board of directors, in accordance with relevant laws, regulations and normative documents such as Shenzhen Stock Exchange gem stock listing rules, Shenzhen Stock Exchange self regulatory guidelines for listed companies No. 2 – standardized operation of GEM listed companies, rules for independent directors of listed companies, etc, And the articles of association and the working system of independent non-executive directors of Pharmaron Beijing Co.Ltd(300759) (Beijing) new drug Technology Co., Ltd. (hereinafter referred to as “the company”). As an independent director of the company, we express our prior approval opinions on the relevant matters considered at the 18th meeting of the second board of directors as follows:
1、 Prior approval opinions on the company’s employment of domestic financial and internal control audit institutions in 2022
Ernst & Young Huaming Certified Public Accountants (special general partnership) has the business qualification related to securities and futures, and has sufficient independence, professional competence, investor protection ability and good integrity record. In the course of practice, the Institute adheres to the principle of independent audit, can objectively, fairly and fairly reflect the company’s financial situation and internal control, and earnestly perform the responsibilities of the audit institution, which is conducive to improving the quality of audit work of listed companies and protecting the interests of listed companies and other shareholders, especially the interests of small and medium-sized shareholders. Therefore, we agree to renew the appointment of Ernst & Young Huaming Certified Public Accountants (special general partnership) as the domestic financial and internal control audit institution of the company in 2022, and agree to submit the matter to the 18th meeting of the second board of directors for deliberation.
2、 Prior approval opinions on the company’s employment of overseas accounting firms in 2022
Ernst & Young certified public accountants is qualified to audit the financial reports of listed companies prepared in accordance with international financial reporting standards and meets the relevant requirements of the stock exchange of Hong Kong. In the course of practice, the Institute adheres to the principle of independent audit, can objectively, fairly and fairly reflect the financial situation of the company, and earnestly performs the responsibilities of the audit institution, which is conducive to improving the quality of audit work of listed companies and protecting the interests of listed companies and other shareholders, especially the interests of minority shareholders. We agree to renew the appointment of Ernst & young as the company’s overseas audit institution in 2022, and agree to submit the matter to the 18th meeting of the second board of directors for deliberation.
3、 Prior approval opinions on the acquisition of 100% equity of domestic companies and related party transactions
The company acquired 100% equity of Beijing Ankai Yibo Biotechnology Co., Ltd. (hereinafter referred to as “Ankai Yibo”) with its own funds in order to further strengthen the quality control of experimental animals, optimize the supply system of experimental animals and improve the company’s ability in bioscience services such as drug safety evaluation. The company’s acquisition of 100% equity of Ankai Yibo does not damage the interests of the company and all shareholders, especially minority shareholders. We agree that the company will purchase 100% equity of Ankai Yibo held by Ms. Chen Jing and Mr. Chen Xuejun with its own funds, and agree to submit the matter to the 18th meeting of the second board of directors for deliberation, and the related directors need to avoid voting. (no text below)
[there is no text on this page, which is the signature page of the prior approval opinions of the independent directors of Pharmaron Beijing Co.Ltd(300759) (Beijing) new drug Technology Co., Ltd. on matters related to the 18th meeting of the second board of directors]
Signature: Signature:
Independent director: Dai Lixin independent director: Chen Guoqin
Signature: Signature:
Independent director: Zeng kunhong independent director: Yu Jian
March 11, 2022
